Pasithea Therapeutics Corp. 10-K — AI Bull & Bear Analysis

The 10-K filing reveals a classic high-risk, high-reward biotech setup where clinical potential is pitted against structural financial fragility. Pasithea has successfully transitioned into a streamlined, single-asset company focused on PAS-004, a candidate that could redefine the standard of care for NF1 and other MAPK-driven diseases if its safety and dosing advantages hold. The company's ability to maintain a multi-year cash runway provides a rare buffer in the clinical-stage space, potentially delaying the need for emergency financing. However, the investment thesis hinges entirely on the 2026-2028 catalyst window. Investors must weigh the potential for a multi-billion dollar market entry against the reality of a cap table designed for maximum dilution and a supply chain centered in a geopolitically volatile region. The overall impact of the filing is a shift from a diversified research firm to a focused clinical gamble, where the primary trade-off is between a breakthrough therapeutic window and the risk of total equity erosion.